Promethean BioPharma are proud to have a partnership with Mynd Life Sciences and Mind Medicine Australia and are supportive of all the work they are doing. In November, Mind Medicine Australia is running a International Summit with very significant speakers to raise awareness of the clinical trials and treatment pathways available. Notably, Dr. Lyle Oberg, a Canadian physician and retired Minister from the Alberta Government will be speaking on genetic markers to be used to guide treatment and to measure success. The Therapeutic Goods Administation (TGA) has already approved some SAS-B treatments and is conducting a schedule review for some of the medications involved, the outcome expected to be finalised in November and published in December. There are links below to a recent TGA studies and circulars on the global advances in this area.

​

​

Links to the TGA:

​

Independent Expert Panel on MDMA and psilocybin.

Notice of interim decisions on proposed amendments to the Poisons Standard - ACMS, ACCS and Joint ACMS-ACCS meetings, November 2020 - 2.4 Psilocybin.

An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders.

​

Mind Medicine Australia have also structured training on the products and treatment pathways available. One training program gives general awareness and the other is more detailed for doctors whom may have a specific interest.

​

Click below to be directed to:

The International Summit on Psychedelic Remedies for Mental Illness - 17-20 November 2021.

The Fundamentals of Psycedelic-Assisted Therapy for Mental Health - Online Course.

Certificate in Psychedelic Assisted Therapy - Training Course.

​

For more information please contact Natasha Hughes through our contact us page.

​